Biostem Technologies (BSEM) Stock Price, News & Analysis

Company Overview

BioStem Technologies, Inc. is a biotechnology company focused on regenerative medicine and biologic products. The company develops and commercializes products intended to support tissue repair and healing, with an emphasis on human tissue-based therapies and related healthcare applications.

Its business includes the development, processing and distribution of regenerative tissue products used by healthcare providers. BioStem has also pursued technologies and product platforms involving stem cells, extracellular matrix materials and other biologic components for applications in wound care, orthopedic procedures and broader regenerative health.

The company serves the healthcare and life sciences markets through relationships with medical professionals, distributors and treatment providers. Publicly available information about its historical operations, geographic reach and current leadership is limited, and specific product availability may change as the company develops its business.

Key Stats

• Today's Range: $2.69 to $3.07
• 50-Day Range: $2.73 to $4.74
• 52-Week Range: $2.25 to $8.40
• Volume: 157,703 shs
• Average Volume: 187,573 shs
• Market Capitalization: $48.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biostem Technologies Stock Analysis - MarketRank™

Biostem Technologies scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biostem Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biostem Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biostem Technologies are expected to grow in the coming year, from ($1.90) to ($1.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biostem Technologies is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of Biostem Technologies has been sold short.

Short Interest Ratio / Days to Cover

Biostem Technologies has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biostem Technologies has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biostem Technologies does not currently pay a dividend.

Dividend Growth

Biostem Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Biostem Technologies this week, compared to 3 articles on an average week.

Search Interest

Only 30 people have searched for BSEM on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

1 people have added Biostem Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biostem Technologies insiders have not sold or bought any company stock.

Percentage Held by Institutions

Biostem Technologies has minimal institutional ownership at this time.

Company Calendar

• Today: 10/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BSEM
• CIK: 1658678
• Web: N/A
• Phone: (954) 380-8342
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.58 million
• Net Margins: -76.02%
• Pretax Margin: N/A
• Return on Equity: -60.22%
• Return on Assets: -34.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $47.48 million
• Price / Sales: 1.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,940,000
• Free Float: N/A
• Market Cap: $48.98 million
• Optionable: N/A
• Beta: 0.17